Hot Investor Mandate 4: Venture Investment Firm Focuses on Early Stage Biotech, Personalized Medicine and Novel Devices

31 Aug

A venture investment firm based in the Mid-Atlantic region of the USA is focused on bridging Eastern and Western innovations and investment opportunities. The firm invests in early to mid-stage biopharma and medtech projects. With its own R&D facilities in China, in-licensing assets from the U.S. and Europe to China would be an important consideration although not requisite for their investment opportunities. With additional strategic investing partners in China, the size of investment can vary depending on the deal. The firm is currently looking for new opportunities globally.

The firm is generally interested in preclinical to phase 1/2 stage assets in biotech and medtech. The firm is open to all therapeutic modalities. Within medtech, the firm is more interested in personalized medicine/companion diagnostics and novel devices. In terms of disease areas, the firm is interested in therapeutics in most therapeutic areas, including autoimmune diseases, cancer, metabolic, liver and gastrointestinal conditions, but the firm generally avoids behavioral illnesses.

The firm is seeking strong management teams with products that could address large unmet medical need. The firm has R&D facilities in China that can facilitate product development and registration both for China local and global market. The firm is open to negotiating regional rights with flexible terms.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: